FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032740916> ?p ?o ?g. }

• W2032740916 endingPage "e90" @default.
• W2032740916 startingPage "e90" @default.
• W2032740916 abstract "Back to table of contents Previous article Next article DepartmentsFull AccessRivastigmine Treatment of Othello Syndrome and Post-ECT Delirium in a Patient With Parkinson’s DiseaseAngela Scicutella, M.D.Angela ScicutellaSearch for more papers by this author, M.D.Published Online:26 Feb 2015https://doi.org/10.1176/appi.neuropsych.14010015AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: A 58-year-old married woman with history of Parkinson’s disease of a 10-year duration marked by right upper extremity rigidity and gait disturbance, but without rest tremor who over the course of her illness, had been treated with amantadine and later pramipexole. She had been stable motorically, cognitively, and psychiatrically until 2 years prior to evaluation, when she had to leave her job as a health care worker on disability. There was no prior psychiatric history, but she became depressed as a result of the job loss and subsequently developed visual hallucinations (a clown figure and the painting “The Scream” by Eduard Munch). More significantly, she developed a delusion that her husband was having an extramarital affair; the patient felt that the mistress came and went via different entrances to their home and was actually in bed with her and her husband, although the patient only sensed her but never actually saw her. She was vigilant about the husband’s whereabouts, and even when he was at work, she was convinced he was with the mistress. The treating neurologist tapered and discontinued pramipexole, and carbidopa/levodopa was substituted as treatment for Parkinson’s disease. Trials of vilazadone and venlafaxine for mood were unsuccessful, and ultimately quetiapine was prescribed for psychosis, but concerns about weight gain prevented further titration of psychotropic medications.Significant findings on the neuropsychiatric examination included persistent delusion about her husband’s infidelity, decreased motivation, sadness about changes in her lifestyle, stooped posture, increased tone of the right upper extremity, and decreased right arm swing. Cognitively, there was poor recall of a short story, impaired copying (pentagons, cube), and frontal lobe deficits (Luria sequence and poor spacing on clock drawing). Increases in the dose of quetiapine up to 100 mg were without benefit; the patient then developed weight loss, anhedonia, and sleep issues, specifically moving in bed and screaming out at night, suggesting REM behavior disorder. The patient refused polysomnography, but empiric treatment with low-dose clonazepam was of benefit.At that point, it had been about 1 year without improvement, so ECT was suggested to address depression with psychotic features. After four ECT treatments, her mood and delusion improved, but by the eight treatment, the patient evidenced confusion in temporal and spatial orientation, poor concentration, and worsening short-term recall. ECT was discontinued due to post-ECT delirium. The patient was then started on a low-dose rivastigmine patch (ACHE-I) with notable improvement in concentration, orientation, and goal-oriented thought processes, but her short-term recall was still impaired. Most significantly, her delusion decreased in intensity and frequency.This case demonstrates an example of Othello syndrome or delusional jealousy, which has been reported in patients with Parkinson’s disease treated with dopamine agonists.1 Often the reduction of the dopamine agonist or treatment with a second-generation antipsychotic (quetiapine) results in improvement,2 but this patient did not benefit. Additionally, this patient developed post-ECT delirium, which has been reported in ECT-treated patients with Parkinson’s disease with depression3; this patient, who had mood and psychotic symptoms, initially improved with ECT, but her cognitive symptoms may have contributed to the subsequent development of delirium. When treated with the ACHE-I, it had the dual benefit of mitigating both the delirium4 and the delusion. In the future, it may be important to consider treating patients with Othello syndrome with ACHE-Is as a first-line treatment approach.Dept. of Psychiatry, NorthShore LIJ Hofstra University School of Medicine, New York, NYCorrespondence: Angela Scicutella, M.D.; e-mail: [email protected]References1 Poletti M, Perugi G, Logi C, et al.: Dopamine agonists and delusional jealousy in Parkinson’s disease: a cross-sectional prevalence study. Mov Disord 2012; 27:1679–1682Crossref, Medline, Google Scholar2 Cannas A, Solla P, Floris G, et al.: Othello syndrome in Parkinson disease patients without dementia. Neurologist 2009; 15:34–36Crossref, Medline, Google Scholar3 Oh JJ, Rummans TA, O’Connor MK, et al.: Cognitive impairment after ECT in patients with Parkinson’s disease and psychiatric illness. (letter) Am J Psychiatry 1992; 149:271Crossref, Medline, Google Scholar4 Logan CJ, Stewart JT: Treatment of post-electroconvulsive therapy delirium and agitation with donepezil. J ECT 2007; 23:28–29Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited byResults from a double blinded, randomised, placebo‐controlled, feasibility trial of melatonin for the treatment of delirium in older medical inpatients11 February 2021 | Internal Medicine Journal, Vol. 51, No. 1Cholinesterase inhibitors for the treatment of delirium in non-ICU settings28 June 2018 | Cochrane Database of Systematic Reviews, Vol. 2018, No. 6Frontiers in Neurology, Vol. 9International Journal of Geriatric Psychiatry, Vol. 32, No. 5Electroconvulsive therapy for depression in Parkinson's disease: systematic review of evidence and recommendationsNeurodegenerative Disease Management, Vol. 6, No. 2 Volume 27Issue 1 Winter 2015Pages e90-e90 Metrics PDF download History Published online 26 February 2015 Published in print 1 January 2015" @default.
• W2032740916 created "2016-06-24" @default.
• W2032740916 creator A5063194395 @default.
• W2032740916 date "2015-01-01" @default.
• W2032740916 modified "2023-09-24" @default.
• W2032740916 title "Rivastigmine Treatment of Othello Syndrome and Post-ECT Delirium in a Patient With Parkinson’s Disease" @default.
• W2032740916 cites W1964783902 @default.
• W2032740916 cites W2076064451 @default.
• W2032740916 cites W2093433915 @default.
• W2032740916 cites W2462702226 @default.
• W2032740916 doi "https://doi.org/10.1176/appi.neuropsych.14010015" @default.
• W2032740916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25716514" @default.
• W2032740916 hasPublicationYear "2015" @default.
• W2032740916 type Work @default.
• W2032740916 sameAs 2032740916 @default.
• W2032740916 citedByCount "5" @default.
• W2032740916 countsByYear W20327409162016 @default.
• W2032740916 countsByYear W20327409162017 @default.
• W2032740916 countsByYear W20327409162018 @default.
• W2032740916 countsByYear W20327409162021 @default.
• W2032740916 crossrefType "journal-article" @default.
• W2032740916 hasAuthorship W2032740916A5063194395 @default.
• W2032740916 hasConcept C118552586 @default.
• W2032740916 hasConcept C126322002 @default.
• W2032740916 hasConcept C15744967 @default.
• W2032740916 hasConcept C2776332859 @default.
• W2032740916 hasConcept C2776976799 @default.
• W2032740916 hasConcept C2777606974 @default.
• W2032740916 hasConcept C2779043874 @default.
• W2032740916 hasConcept C2779134260 @default.
• W2032740916 hasConcept C2779177420 @default.
• W2032740916 hasConcept C2779483572 @default.
• W2032740916 hasConcept C2779547902 @default.
• W2032740916 hasConcept C2779734285 @default.
• W2032740916 hasConcept C2779753318 @default.
• W2032740916 hasConcept C2779989193 @default.
• W2032740916 hasConcept C2780304432 @default.
• W2032740916 hasConcept C2780904820 @default.
• W2032740916 hasConcept C2908998935 @default.
• W2032740916 hasConcept C71924100 @default.
• W2032740916 hasConceptScore W2032740916C118552586 @default.
• W2032740916 hasConceptScore W2032740916C126322002 @default.
• W2032740916 hasConceptScore W2032740916C15744967 @default.
• W2032740916 hasConceptScore W2032740916C2776332859 @default.
• W2032740916 hasConceptScore W2032740916C2776976799 @default.
• W2032740916 hasConceptScore W2032740916C2777606974 @default.
• W2032740916 hasConceptScore W2032740916C2779043874 @default.
• W2032740916 hasConceptScore W2032740916C2779134260 @default.
• W2032740916 hasConceptScore W2032740916C2779177420 @default.
• W2032740916 hasConceptScore W2032740916C2779483572 @default.
• W2032740916 hasConceptScore W2032740916C2779547902 @default.
• W2032740916 hasConceptScore W2032740916C2779734285 @default.
• W2032740916 hasConceptScore W2032740916C2779753318 @default.
• W2032740916 hasConceptScore W2032740916C2779989193 @default.
• W2032740916 hasConceptScore W2032740916C2780304432 @default.
• W2032740916 hasConceptScore W2032740916C2780904820 @default.
• W2032740916 hasConceptScore W2032740916C2908998935 @default.
• W2032740916 hasConceptScore W2032740916C71924100 @default.
• W2032740916 hasIssue "1" @default.
• W2032740916 hasLocation W20327409161 @default.
• W2032740916 hasLocation W20327409162 @default.
• W2032740916 hasOpenAccess W2032740916 @default.
• W2032740916 hasPrimaryLocation W20327409161 @default.
• W2032740916 hasRelatedWork W2013658504 @default.
• W2032740916 hasRelatedWork W2014392059 @default.
• W2032740916 hasRelatedWork W2032740916 @default.
• W2032740916 hasRelatedWork W2045632851 @default.
• W2032740916 hasRelatedWork W2048576906 @default.
• W2032740916 hasRelatedWork W2336345899 @default.
• W2032740916 hasRelatedWork W2412813187 @default.
• W2032740916 hasRelatedWork W2782759134 @default.
• W2032740916 hasRelatedWork W3125638541 @default.
• W2032740916 hasRelatedWork W4236494730 @default.
• W2032740916 hasVolume "27" @default.
• W2032740916 isParatext "false" @default.
• W2032740916 isRetracted "false" @default.
• W2032740916 magId "2032740916" @default.
• W2032740916 workType "article" @default.